Immunogen design for HIV-1 and influenza

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 11, 2014, Pages 1891-1906

  Rathore, Ujjwal ^a   Kesavardhana, Sannula ^a   Mallajosyula, V Vamsee Aditya ^a   Varadarajan, Raghavan ^a,b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Glycosylation; Native trimer; Protein minimization; Stability; Vaccine

Indexed keywords

ENVELOPE PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; SUBUNIT VACCINE;

ANTIBODY ENGINEERING; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DRUG BINDING SITE; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GERM LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; NONHUMAN; PHYLOGENETIC TREE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; REVIEW; SEQUENCE ALIGNMENT; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 84907933022     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.05.010     Document Type: Review

References (226)

1. I.J. Amanna, and M.K. Slifka Wanted, dead or alive: new viral vaccines Antivir. Res. 84 2009 119 130
2. R.H. Gray, M.J. Wawer, R. Brookmeyer, N.K. Sewankambo, D. Serwadda, F. Wabwire-Mangen, T. Lutalo, X. Li, T. vanCott, and T.C. Quinn Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda Lancet 357 2001 1149 1153
3. W.J. Ma, J.J. Wang, K.H. Reilly, A.M. Bi, G.W. Ding, K. Smith, and N. Wang Estimation of probability of unprotected heterosexual vaginal transmission of HIV-1 from clients to female sex workers in Kaiyuan, Yunnan Province, China Biomed. Environ. Sci. 23 2010 287 292
4. A. Forsman, and R.A. Weiss Why is HIV a pathogen? Trends Microbiol. 16 2008 555 560
5. A.E. Fiore, C.B. Bridges, and N.J. Cox Seasonal influenza vaccines Curr. Top. Microbiol. Immunol. 333 2009 43 82
6. B.G. Turner, and M.F. Summers Structural biology of HIV J. Mol. Biol. 285 1999 1 32
7. J.C. Plantier, M. Leoz, J.E. Dickerson, F. De Oliveira, F. Cordonnier, V. Lemee, F. Damond, D.L. Robertson, and F. Simon A new human immunodeficiency virus derived from gorillas Nat. Med. 15 2009 871 872
8. P.M. Sharp, and B.H. Hahn Origins of HIV and the AIDS pandemic Cold Spring Harb. Perspect. Med. 1 2011 a006841
9. D.L. Robertson, J.P. Anderson, J.A. Bradac, J.K. Carr, B. Foley, R.K. Funkhouser, F. Gao, B.H. Hahn, M.L. Kalish, C. Kuiken, G.H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P.M. Sharp, S. Wolinsky, and B. Korber HIV-1 nomenclature proposal Science 288 2000 55 56
10. M. Peeters The genetic variability of HIV-1 and its implications Transfus. Clin. Biol. 8 2001 222 225
11. L. Buonaguro, M.L. Tornesello, and F.M. Buonaguro Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications J. Virol. 81 2007 10209 10219
12. D.D. Richman, T. Wrin, S.J. Little, and C.J. Petropoulos Rapid evolution of the neutralizing antibody response to HIV type 1 infection Proc. Natl. Acad. Sci. U. S. A. 100 2003 4144 4149
13. I. Mikell, D.N. Sather, S.A. Kalams, M. Altfeld, G. Alter, and L. Stamatatos Characteristics of the earliest cross-neutralizing antibody response to HIV-1 PLoS Pathog. 7 2011 e1001251
14. X. Wei, J.M. Decker, S. Wang, H. Hui, J.C. Kappes, X. Wu, J.F. Salazar-Gonzalez, M.G. Salazar, J.M. Kilby, M.S. Saag, N.L. Komarova, M.A. Nowak, B.H. Hahn, P.D. Kwong, and G.M. Shaw Antibody neutralization and escape by HIV-1 Nature 422 2003 307 312
15. G. Alter, and M.A. Moody The humoral response to HIV-1: new insights, renewed focus J. Infect. Dis. 202 Suppl. 2 2010 S315 S322
16. J.S. Klein, and P.J. Bjorkman Few and far between: how HIV may be evading antibody avidity PLoS Pathog. 6 2010 e1000908
17. D.R. Burton, R. Ahmed, D.H. Barouch, S.T. Butera, S. Crotty, A. Godzik, D.E. Kaufmann, M.J. McElrath, M.C. Nussenzweig, B. Pulendran, C.N. Scanlan, W.R. Schief, G. Silvestri, H. Streeck, B.D. Walker, L.M. Walker, A.B. Ward, I.A. Wilson, and R. Wyatt A blueprint for HIV vaccine discovery Cell Host Microbe 12 2012 396 407
18. J. Liu, A. Bartesaghi, M.J. Borgnia, G. Sapiro, and S. Subramaniam Molecular architecture of native HIV-1 gp120 trimers Nature 455 2008 109 113
19. R. Pantophlet, and D.R. Burton GP120: target for neutralizing HIV-1 antibodies Annu. Rev. Immunol. 24 2006 739 769
20. A.G. Dalgleish, P.C. Beverley, P.R. Clapham, D.H. Crawford, M.F. Greaves, and R.A. Weiss The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus Nature 312 1984 763 767
21. P.D. Kwong, R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody Nature 393 1998 648 659
22. R.W. Doms Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection Virology 276 2000 229 237
23. P.R. Clapham, and R.A. Weiss Immunodeficiency viruses. Spoilt for choice of co-receptors Nature 388 1997 230 231
24. M.H. Malim, and M. Emerman HIV-1 sequence variation: drift, shift, and attenuation Cell 104 2001 469 472
25. T. Ndung'u, and R.A. Weiss On HIV diversity AIDS 26 2012 1255 1260
26. B. Korber, B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours Evolutionary and immunological implications of contemporary HIV-1 variation Br. Med. Bull. 58 2001 19 42
27. C.K. Leonard, M.W. Spellman, L. Riddle, R.J. Harris, J.N. Thomas, and T.J. Gregory Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells J. Biol. Chem. 265 1990 10373 10382
28. M. Igarashi, K. Ito, H. Kida, and A. Takada Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin Virology 376 2008 323 329
29. S.R. Das, P. Puigbo, S.E. Hensley, D.E. Hurt, J.R. Bennink, and J.W. Yewdell Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain PLoS Pathog. 6 2010 e1001211
30. A. Trkola, M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J.P. Moore, and H. Katinger Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 J. Virol. 70 1996 1100 1108
31. P.L. Moore, E.S. Gray, C.K. Wibmer, J.N. Bhiman, M. Nonyane, D.J. Sheward, T. Hermanus, S. Bajimaya, N.L. Tumba, M.R. Abrahams, B.E. Lambson, N. Ranchobe, L. Ping, N. Ngandu, Q. Abdool Karim, S.S. Abdool Karim, R.I. Swanstrom, M.S. Seaman, C. Williamson, and L. Morris Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape Nat. Med. 18 2012 1688 1692
32. R.I. Connor, B.T. Korber, B.S. Graham, B.H. Hahn, D.D. Ho, B.D. Walker, A.U. Neumann, S.H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K.J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J.P. Moore, and S.M. Wolinsky Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines J. Virol. 72 1998 1552 1576
33. P.D. Kwong, M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, H. Katinger, P.W. Parren, J. Robinson, D. Van Ryk, L. Wang, D.R. Burton, E. Freire, R. Wyatt, J. Sodroski, W.A. Hendrickson, and J. Arthos HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 2002 678 682
34. S.H. Xiang, P.D. Kwong, R. Gupta, C.D. Rizzuto, D.J. Casper, R. Wyatt, L. Wang, W.A. Hendrickson, M.L. Doyle, and J. Sodroski Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein J. Virol. 76 2002 9888 9899
35. M.J. van Gils, Z. Euler, B. Schweighardt, T. Wrin, and H. Schuitemaker Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression AIDS 23 2009 2405 2414
36. M.D. Simek, W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, J. Birungi, A. Pozniak, D.A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L.G. Bekker, P. Pitisuttithum, R. Paris, L.M. Walker, P. Poignard, T. Wrin, P.E. Fast, D.R. Burton, and W.C. Koff Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm J. Virol. 83 2009 7337 7348
37. F. Klein, H. Mouquet, P. Dosenovic, J.F. Scheid, L. Scharf, and M.C. Nussenzweig Antibodies in HIV-1 vaccine development and therapy Science 341 2013 1199 1204
38. E.O. Saphire, P.W. Parren, R. Pantophlet, M.B. Zwick, G.M. Morris, P.M. Rudd, R.A. Dwek, R.L. Stanfield, D.R. Burton, and I.A. Wilson Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design Science 293 2001 1155 1159
39. T. Zhou, I. Georgiev, X. Wu, Z.Y. Yang, K. Dai, A. Finzi, Y.D. Kwon, J.F. Scheid, W. Shi, L. Xu, Y. Yang, J. Zhu, M.C. Nussenzweig, J. Sodroski, L. Shapiro, G.J. Nabel, J.R. Mascola, and P.D. Kwong Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01 Science 329 2010 811 817
40. J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D.R. Burton, F. Pereyra, D.D. Ho, B.D. Walker, M.S. Seaman, P.J. Bjorkman, B.T. Chait, and M.C. Nussenzweig Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding Science 333 2011 1633 1637
41. X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N.S. Longo, M. Louder, K. McKee, S. O'Dell, S. Perfetto, S.D. Schmidt, W. Shi, L. Wu, Y. Yang, Z.Y. Yang, Z. Yang, Z. Zhang, M. Bonsignori, J.A. Crump, S.H. Kapiga, N.E. Sam, B.F. Haynes, M. Simek, D.R. Burton, W.C. Koff, N.A. Doria-Rose, M. Connors, J.C. Mullikin, G.J. Nabel, M. Roederer, L. Shapiro, P.D. Kwong, and J.R. Mascola Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing Science 333 2011 1593 1602
42. D. Corti, J.P. Langedijk, A. Hinz, M.S. Seaman, F. Vanzetta, B.M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla-Jhagjhoorsingh, B. Willems, M.J. Zekveld, H. Dreja, E. O'Sullivan, C. Pade, C. Orkin, S.A. Jeffs, D.C. Montefiori, D. Davis, W. Weissenhorn, A. McKnight, J.L. Heeney, F. Sallusto, Q.J. Sattentau, R.A. Weiss, and A. Lanzavecchia Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals PLoS One 5 2010 e8805
43. H.X. Liao, R. Lynch, T. Zhou, F. Gao, S.M. Alam, S.D. Boyd, A.Z. Fire, K.M. Roskin, C.A. Schramm, Z. Zhang, J. Zhu, L. Shapiro, J.C. Mullikin, S. Gnanakaran, P. Hraber, K. Wiehe, G. Kelsoe, G. Yang, S.M. Xia, D.C. Montefiori, R. Parks, K.E. Lloyd, R.M. Scearce, K.A. Soderberg, M. Cohen, G. Kamanga, M.K. Louder, L.M. Tran, Y. Chen, F. Cai, S. Chen, S. Moquin, X. Du, M.G. Joyce, S. Srivatsan, B. Zhang, A. Zheng, G.M. Shaw, B.H. Hahn, T.B. Kepler, B.T. Korber, P.D. Kwong, J.R. Mascola, and B.F. Haynes Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus Nature 496 2013 469 476
44. L.M. Walker, S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, J.K. Lehrman, F.H. Priddy, O.A. Olsen, S.M. Frey, P.W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W.C. Koff, P. Poignard, and D.R. Burton Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target Science 326 2009 285 289
45. L.M. Walker, M. Huber, K.J. Doores, E. Falkowska, R. Pejchal, J.P. Julien, S.K. Wang, A. Ramos, P.Y. Chan-Hui, M. Moyle, J.L. Mitcham, P.W. Hammond, O.A. Olsen, P. Phung, S. Fling, C.H. Wong, S. Phogat, T. Wrin, M.D. Simek, W.C. Koff, I.A. Wilson, D.R. Burton, and P. Poignard Broad neutralization coverage of HIV by multiple highly potent antibodies Nature 477 2011 466 470
46. M. Bonsignori, K.K. Hwang, X. Chen, C.Y. Tsao, L. Morris, E. Gray, D.J. Marshall, J.A. Crump, S.H. Kapiga, N.E. Sam, F. Sinangil, M. Pancera, Y. Yongping, B. Zhang, J. Zhu, P.D. Kwong, S. O'Dell, J.R. Mascola, L. Wu, G.J. Nabel, S. Phogat, M.S. Seaman, J.F. Whitesides, M.A. Moody, G. Kelsoe, X. Yang, J. Sodroski, G.M. Shaw, D.C. Montefiori, T.B. Kepler, G.D. Tomaras, S.M. Alam, H.X. Liao, and B.F. Haynes Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors J. Virol. 85 2011 9998 10009
47. T. Muster, F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 J. Virol. 67 1993 6642 6647
48. G. Stiegler, R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1 AIDS Res. Hum. Retrovir. 17 2001 1757 1765
49. J. Huang, G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, H. Imamichi, R.T. Bailer, B. Chakrabarti, S.K. Sharma, S.M. Alam, T. Wang, Y. Yang, B. Zhang, S.A. Migueles, R. Wyatt, B.F. Haynes, P.D. Kwong, J.R. Mascola, and M. Connors Broad and potent neutralization of HIV-1 by a gp41-specific human antibody Nature 491 2012 406 412
50. D.H. Barouch, J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, S. Gupta, J.P. Nkolola, M.S. Seaman, K.M. Smith, E.N. Borducchi, C. Cabral, J.Y. Smith, S. Blackmore, S. Sanisetty, J.R. Perry, M. Beck, M.G. Lewis, W. Rinaldi, A.K. Chakraborty, P. Poignard, M.C. Nussenzweig, and D.R. Burton Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys Nature 503 2013 224 228
51. M. Shingai, Y. Nishimura, F. Klein, H. Mouquet, O.K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak Jr., J.D. Lifson, D.S. Dimitrov, M.C. Nussenzweig, and M.A. Martin Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia Nature 503 2013 277 280
52. J.A. Horwitz, A. Halper-Stromberg, H. Mouquet, A.D. Gitlin, A. Tretiakova, T.R. Eisenreich, M. Malbec, S. Gravemann, E. Billerbeck, M. Dorner, H. Buning, O. Schwartz, E. Knops, R. Kaiser, M.S. Seaman, J.M. Wilson, C.M. Rice, A. Ploss, P.J. Bjorkman, F. Klein, and M.C. Nussenzweig HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice Proc. Natl. Acad. Sci. U. S. A. 110 2013 16538 16543
53. B.F. Haynes, J. Fleming, E.W. St Clair, H. Katinger, G. Stiegler, R. Kunert, J. Robinson, R.M. Scearce, K. Plonk, H.F. Staats, T.L. Ortel, H.X. Liao, and S.M. Alam Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies Science 308 2005 1906 1908
54. E.J. Platt, K. Wehrly, S.E. Kuhmann, B. Chesebro, and D. Kabat Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 J. Virol. 72 1998 2855 2864
55. X. Wei, J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 2002 1896 1905
56. D.C. Montefiori Measuring HIV neutralization in a luciferase reporter gene assay Methods Mol. Biol. 485 2009 395 405
57. R. Willey, M.C. Nason, Y. Nishimura, D.A. Follmann, and M.A. Martin Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay AIDS Res. Hum. Retrovir. 26 2010 89 98
58. J.P. Julien, A. Cupo, D. Sok, R.L. Stanfield, D. Lyumkis, M.C. Deller, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, A.B. Ward, and I.A. Wilson Crystal structure of a soluble cleaved HIV-1 envelope trimer Science 342 2013 1477 1483
59. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612
60. N.M. Flynn, D.N. Forthal, C.D. Harro, F.N. Judson, K.H. Mayer, and M.F. Para Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J. Infect. Dis. 191 2005 654 665
61. A.M. Schultz, and J.A. Bradac The HIV vaccine pipeline, from preclinical to phase III AIDS 15 Suppl. 5 2001 S147 S158
62. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J.W. Tappero, and K. Choopanya Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand J. Infect. Dis. 194 2006 1661 1671
63. B.F. Haynes, P.B. Gilbert, M.J. McElrath, S. Zolla-Pazner, G.D. Tomaras, S.M. Alam, D.T. Evans, D.C. Montefiori, C. Karnasuta, R. Sutthent, H.X. Liao, A.L. DeVico, G.K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M.L. Robb, V. Ngauy, M.S. de Souza, R. Paris, G. Ferrari, R.T. Bailer, K.A. Soderberg, C. Andrews, P.W. Berman, N. Frahm, S.C. De Rosa, M.D. Alpert, N.L. Yates, X. Shen, R.A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N.L. Michael, and J.H. Kim Immune-correlates analysis of an HIV-1 vaccine efficacy trial N. Engl. J. Med. 366 2012 1275 1286
64. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J.G. McNeil, D.P. Francis, D. Stablein, D.L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M.L. Robb, N.L. Michael, P. Kunasol, and J.H. Kim Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand N. Engl. J. Med. 361 2009 2209 2220
65. D.C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M.S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, M.A. Moody, M. Bonsignori, C. Ochsenbauer, J. Kappes, H. Tang, K. Greene, H. Gao, C.C. LaBranche, C. Andrews, V.R. Polonis, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, S.G. Self, P.W. Berman, D. Francis, F. Sinangil, C. Lee, J. Tartaglia, M.L. Robb, B.F. Haynes, N.L. Michael, and J.H. Kim Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials J. Infect. Dis. 206 2012 431 441
66. M. Pancera, and R. Wyatt Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage Virology 332 2005 145 156
67. B.K. Chakrabarti, M. Pancera, S. Phogat, S. O'Dell, K. McKee, J. Guenaga, J. Robinson, J. Mascola, and R.T. Wyatt HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies AIDS Res. Hum. Retrovir. 27 2011 877 887
68. B.K. Chakrabarti, Y. Feng, S.K. Sharma, K. McKee, G.B. Karlsson Hedestam, C.C. Labranche, D.C. Montefiori, J.R. Mascola, and R.T. Wyatt Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates J. Virol. 87 2013 13239 13251
69. D.C. Chan, D. Fass, J.M. Berger, and P.S. Kim Core structure of gp41 from the HIV envelope glycoprotein Cell 89 1997 263 273
70. E.T. Crooks, T. Tong, K. Osawa, and J.M. Binley Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected J. Virol. 85 2011 5825 5839
71. T. Tong, E.T. Crooks, K. Osawa, and J.M. Binley HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes J. Virol. 86 2012 3574 3587
72. X. Yang, M. Farzan, R. Wyatt, and J. Sodroski Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins J. Virol. 74 2000 5716 5725
73. C.W. Zhang, Y. Chishti, R.E. Hussey, and E.L. Reinherz Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer J. Biol. Chem. 276 2001 39577 39585
74. I.K. Srivastava, L. Stamatatos, H. Legg, E. Kan, A. Fong, S.R. Coates, L. Leung, M. Wininger, J.J. Donnelly, J.B. Ulmer, and S.W. Barnett Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus J. Virol. 76 2002 2835 2847
75. J.M. Kovacs, J.P. Nkolola, H. Peng, A. Cheung, J. Perry, C.A. Miller, M.S. Seaman, D.H. Barouch, and B. Chen HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120 Proc. Natl. Acad. Sci. U. S. A. 109 2012 12111 12116
76. X. Yang, L. Florin, M. Farzan, P. Kolchinsky, P.D. Kwong, J. Sodroski, and R. Wyatt Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution J. Virol. 74 2000 4746 4754
77. B. Chen, Y. Cheng, L. Calder, S.C. Harrison, E.L. Reinherz, J.J. Skehel, and D.C. Wiley A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase J. Virol. 78 2004 4508 4516
78. X. Yang, J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, and J. Sodroski Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin J. Virol. 76 2002 4634 4642
79. R.W. Sanders, L. Schiffner, A. Master, F. Kajumo, Y. Guo, T. Dragic, J.P. Moore, and J.M. Binley Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits J. Virol. 74 2000 5091 5100
80. J.M. Binley, R.W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D.J. Anselma, P.J. Maddon, W.C. Olson, and J.P. Moore A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure J. Virol. 74 2000 627 643
81. R.W. Sanders, M. Vesanen, N. Schuelke, A. Master, L. Schiffner, R. Kalyanaraman, M. Paluch, B. Berkhout, P.J. Maddon, W.C. Olson, M. Lu, and J.P. Moore Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 J. Virol. 76 2002 8875 8889
82. N. Schulke, M.S. Vesanen, R.W. Sanders, P. Zhu, M. Lu, D.J. Anselma, A.R. Villa, P.W. Parren, J.M. Binley, K.H. Roux, P.J. Maddon, J.P. Moore, and W.C. Olson Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein J. Virol. 76 2002 7760 7776
83. S. Beddows, N. Schulke, M. Kirschner, K. Barnes, M. Franti, E. Michael, T. Ketas, R.W. Sanders, P.J. Maddon, W.C. Olson, and J.P. Moore Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 J. Virol. 79 2005 8812 8827
84. S.P. Iyer, M. Franti, A.A. Krauchuk, D.N. Fisch, A.A. Ouattara, K.H. Roux, L. Krawiec, A.K. Dey, S. Beddows, P.J. Maddon, J.P. Moore, and W.C. Olson Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers AIDS Res. Hum. Retrovir. 23 2007 817 828
85. P.J. Klasse, R.S. Depetris, R. Pejchal, J.P. Julien, R. Khayat, J.H. Lee, A.J. Marozsan, A. Cupo, N. Cocco, J. Korzun, A. Yasmeen, A.B. Ward, I.A. Wilson, R.W. Sanders, and J.P. Moore Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein J. Virol. 87 2013 9873 9885
86. A. Harris, M.J. Borgnia, D. Shi, A. Bartesaghi, H. He, R. Pejchal, Y.K. Kang, R. Depetris, A.J. Marozsan, R.W. Sanders, P.J. Klasse, J.L. Milne, I.A. Wilson, W.C. Olson, J.P. Moore, and S. Subramaniam Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures Proc. Natl. Acad. Sci. U. S. A. 108 2011 11440 11445
87. J.M. Binley, R.W. Sanders, A. Master, C.S. Cayanan, C.L. Wiley, L. Schiffner, B. Travis, S. Kuhmann, D.R. Burton, S.L. Hu, W.C. Olson, and J.P. Moore Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins J. Virol. 76 2002 2606 2616
88. S. Beddows, M. Franti, A.K. Dey, M. Kirschner, S.P. Iyer, D.C. Fisch, T. Ketas, E. Yuste, R.C. Desrosiers, P.J. Klasse, P.J. Maddon, W.C. Olson, and J.P. Moore A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120 Virology 360 2007 329 340
89. R.W. Sanders, R. Derking, A. Cupo, J.P. Julien, A. Yasmeen, N. de Val, H.J. Kim, C. Blattner, A.T. de la Pena, J. Korzun, M. Golabek, K. de Los Reyes, T.J. Ketas, M.J. van Gils, C.R. King, I.A. Wilson, A.B. Ward, P.J. Klasse, and J.P. Moore A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies PLoS Pathog. 9 2013 e1003618
90. P. Saha, S. Bhattacharyya, S. Kesavardhana, E.R. Miranda, P.S. Ali, D. Sharma, and R. Varadarajan Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design Biochemistry 51 2012 1836 1847
91. D. Lyumkis, J.P. Julien, N. de Val, A. Cupo, C.S. Potter, P.J. Klasse, D.R. Burton, R.W. Sanders, J.P. Moore, B. Carragher, I.A. Wilson, and A.B. Ward Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer Science 342 2013 1484 1490
92. A. Bartesaghi, A. Merk, M.J. Borgnia, J.L. Milne, and S. Subramaniam Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy Nat. Struct. Mol. Biol. 20 2013 1352 1357
93. X. Xiao, W. Chen, Y. Feng, and D.S. Dimitrov Maturation pathways of cross-reactive HIV-1 neutralizing antibodies Viruses 1 2009 802 817
94. J.F. Scheid, H. Mouquet, N. Feldhahn, M.S. Seaman, K. Velinzon, J. Pietzsch, R.G. Ott, R.M. Anthony, H. Zebroski, A. Hurley, A. Phogat, B. Chakrabarti, Y. Li, M. Connors, F. Pereyra, B.D. Walker, H. Wardemann, D. Ho, R.T. Wyatt, J.R. Mascola, J.V. Ravetch, and M.C. Nussenzweig Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Nature 458 2009 636 640
95. L.E. McCoy, and R.A. Weiss Neutralizing antibodies to HIV-1 induced by immunization J. Exp. Med. 210 2013 209 223
96. M. Kirschner, V. Monrose, M. Paluch, N. Techodamrongsin, A. Rethwilm, and J.P. Moore The production of cleaved, trimeric human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein vaccine antigens and infectious pseudoviruses using linear polyethylenimine as a transfection reagent Protein Expr. Purif. 48 2006 61 68
97. P. Poignard, M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P.W. Parren, and D.R. Burton Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies J. Virol. 77 2003 353 365
98. N. Agrawal, D.P. Leaman, E. Rowcliffe, H. Kinkead, R. Nohria, J. Akagi, K. Bauer, S.X. Du, R.G. Whalen, D.R. Burton, and M.B. Zwick Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1) PLoS One 6 2011 e21339
99. D.P. Leaman, and M.B. Zwick Increased functional stability and homogeneity of viral envelope spikes through directed evolution PLoS Pathog. 9 2013 e1003184
100. G. Ofek, F.J. Guenaga, W.R. Schief, J. Skinner, D. Baker, R. Wyatt, and P.D. Kwong Elicitation of structure-specific antibodies by epitope scaffolds Proc. Natl. Acad. Sci. U. S. A. 107 2010 17880 17887
101. M.L. Azoitei, B.E. Correia, Y.E. Ban, C. Carrico, O. Kalyuzhniy, L. Chen, A. Schroeter, P.S. Huang, J.S. McLellan, P.D. Kwong, D. Baker, R.K. Strong, and W.R. Schief Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold Science 334 2011 373 376
102. L.X. Wang Synthetic carbohydrate antigens for HIV vaccine design Curr. Opin. Chem. Biol. 17 2013 997 1005
103. M.N. Amin, J.S. McLellan, W. Huang, J. Orwenyo, D.R. Burton, W.C. Koff, P.D. Kwong, and L.X. Wang Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies Nat. Chem. Biol. 9 2013 521 526
104. I.J. Krauss, J.G. Joyce, A.C. Finnefrock, H.C. Song, V.Y. Dudkin, X. Geng, J.D. Warren, M. Chastain, J.W. Shiver, and S.J. Danishefsky Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody J. Am. Chem. Soc. 129 2007 11042 11044
105. J.G. Joyce, I.J. Krauss, H.C. Song, D.W. Opalka, K.M. Grimm, D.D. Nahas, M.T. Esser, R. Hrin, M. Feng, V.Y. Dudkin, M. Chastain, J.W. Shiver, and S.J. Danishefsky An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions Proc. Natl. Acad. Sci. U. S. A. 105 2008 15684 15689
106. B. Aussedat, Y. Vohra, P.K. Park, A. Fernandez-Tejada, S.M. Alam, S.M. Dennison, F.H. Jaeger, K. Anasti, S. Stewart, J.H. Blinn, H.X. Liao, J.G. Sodroski, B.F. Haynes, and S.J. Danishefsky Chemical synthesis of highly congested gp120 V1V2 N-glycopeptide antigens for potential HIV-1-directed vaccines J. Am. Chem. Soc. 135 2013 13113 13120
107. S.M. Alam, S.M. Dennison, B. Aussedat, Y. Vohra, P.K. Park, A. Fernandez-Tejada, S. Stewart, F.H. Jaeger, K. Anasti, J.H. Blinn, T.B. Kepler, M. Bonsignori, H.X. Liao, J.G. Sodroski, S.J. Danishefsky, and B.F. Haynes Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors Proc. Natl. Acad. Sci. U. S. A. 110 2013 18214 18219
108. T. Zhou, L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, S.H. Xiang, X. Yang, M.Y. Zhang, M.B. Zwick, J. Arthos, D.R. Burton, D.S. Dimitrov, J. Sodroski, R. Wyatt, G.J. Nabel, and P.D. Kwong Structural definition of a conserved neutralization epitope on HIV-1 gp120 Nature 445 2007 732 737
109. C.F. Barbas III, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T.M. Jones, S.L. Zebedee, M.A. Persson, P.L. Nara, and E. Norrby Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro Proc. Natl. Acad. Sci. U. S. A. 89 1992 9339 9343
110. J.M. Binley, T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C.J. Petropoulos, and D.R. Burton Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies J. Virol. 78 2004 13232 13252
111. P. Roben, J.P. Moore, M. Thali, J. Sodroski, C.F. Barbas III, and D.R. Burton Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 J. Virol. 68 1994 4821 4828
112. X. Wu, Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, N.S. Longo, K. McKee, S. O'Dell, M.K. Louder, D.L. Wycuff, Y. Feng, M. Nason, N. Doria-Rose, M. Connors, P.D. Kwong, M. Roederer, R.T. Wyatt, G.J. Nabel, and J.R. Mascola Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 Science 329 2010 856 861
113. R. Diskin, J.F. Scheid, P.M. Marcovecchio, A.P. West Jr., F. Klein, H. Gao, P.N. Gnanapragasam, A. Abadir, M.S. Seaman, M.C. Nussenzweig, and P.J. Bjorkman Increasing the potency and breadth of an HIV antibody by using structure-based rational design Science 334 2011 1289 1293
114. L. Kong, J.H. Lee, K.J. Doores, C.D. Murin, J.P. Julien, R. McBride, Y. Liu, A. Marozsan, A. Cupo, P.J. Klasse, S. Hoffenberg, M. Caulfield, C.R. King, Y. Hua, K.M. Le, R. Khayat, M.C. Deller, T. Clayton, H. Tien, T. Feizi, R.W. Sanders, J.C. Paulson, J.P. Moore, R.L. Stanfield, D.R. Burton, A.B. Ward, and I.A. Wilson Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 Nat. Struct. Mol. Biol. 20 2013 796 803
115. R. Pejchal, K.J. Doores, L.M. Walker, R. Khayat, P.S. Huang, S.K. Wang, R.L. Stanfield, J.P. Julien, A. Ramos, M. Crispin, R. Depetris, U. Katpally, A. Marozsan, A. Cupo, S. Maloveste, Y. Liu, R. McBride, Y. Ito, R.W. Sanders, C. Ogohara, J.C. Paulson, T. Feizi, C.N. Scanlan, C.H. Wong, J.P. Moore, W.C. Olson, A.B. Ward, P. Poignard, W.R. Schief, D.R. Burton, and I.A. Wilson A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield Science 334 2011 1097 1103
116. J.P. Julien, D. Sok, R. Khayat, J.H. Lee, K.J. Doores, L.M. Walker, A. Ramos, D.C. Diwanji, R. Pejchal, A. Cupo, U. Katpally, R.S. Depetris, R.L. Stanfield, R. McBride, A.J. Marozsan, J.C. Paulson, R.W. Sanders, J.P. Moore, D.R. Burton, P. Poignard, A.B. Ward, and I.A. Wilson Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans PLoS Pathog. 9 2013 e1003342
117. R.W. Sanders, M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K.O. Lloyd, P.D. Kwong, and J.P. Moore The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120 J. Virol. 76 2002 7293 7305
118. X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M.K. Gorny, S. Zolla-Pazner, and J. Sodroski Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1 J. Virol. 78 2004 12975 12986
119. L. Wu, T. Zhou, Z.Y. Yang, K. Svehla, S. O'Dell, M.K. Louder, L. Xu, J.R. Mascola, D.R. Burton, J.A. Hoxie, R.W. Doms, P.D. Kwong, and G.J. Nabel Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain J. Virol. 83 2009 5077 5086
120. S. Bhattacharyya, R.E. Rajan, Y. Swarupa, U. Rathore, A. Verma, R. Udaykumar, and R. Varadarajan Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies J. Biol. Chem. 285 2010 27100 27110
121. Y. Li, L. Luo, N. Rasool, and C.Y. Kang Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding J. Virol. 67 1993 584 588
122. P.D. Kwong, R. Wyatt, S. Majeed, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates Structure 8 2000 1329 1339
123. S. Bhattacharyya, P. Singh, U. Rathore, M. Purwar, D. Wagner, H. Arendt, J. DeStefano, C.C. LaBranche, D.C. Montefiori, S. Phogat, and R. Varadarajan Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies J. Biol. Chem. 288 2013 9815 9825
124. M.J. van Gils, and R.W. Sanders Broadly neutralizing antibodies against HIV-1: templates for a vaccine Virology 435 2013 46 56
125. E.S. Gray, M.C. Madiga, T. Hermanus, P.L. Moore, C.K. Wibmer, N.L. Tumba, L. Werner, K. Mlisana, S. Sibeko, C. Williamson, S.S. Abdool Karim, and L. Morris The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4 + T cell decline and high viral load during acute infection J. Virol. 85 2011 4828 4840
126. S. Hoot, A.T. McGuire, K.W. Cohen, R.K. Strong, L. Hangartner, F. Klein, R. Diskin, J.F. Scheid, D.N. Sather, D.R. Burton, and L. Stamatatos Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs PLoS Pathog. 9 2013 e1003106
127. M. Pancera, J.S. McLellan, X. Wu, J. Zhu, A. Changela, S.D. Schmidt, Y. Yang, T. Zhou, S. Phogat, J.R. Mascola, and P.D. Kwong Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1 J. Virol. 84 2010 8098 8110
128. M.A. Moody, R. Zhang, E.B. Walter, C.W. Woods, G.S. Ginsburg, M.T. McClain, T.N. Denny, X. Chen, S. Munshaw, D.J. Marshall, J.F. Whitesides, M.S. Drinker, J.D. Amos, T.C. Gurley, J.A. Eudailey, A. Foulger, K.R. DeRosa, R. Parks, R.R. Meyerhoff, J.S. Yu, D.M. Kozink, B.E. Barefoot, E.A. Ramsburg, S. Khurana, H. Golding, N.A. Vandergrift, S.M. Alam, G.D. Tomaras, T.B. Kepler, G. Kelsoe, H.X. Liao, and B.F. Haynes H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination PLoS One 6 2011 e25797
129. D. Lingwood, P.M. McTamney, H.M. Yassine, J.R. Whittle, X. Guo, J.C. Boyington, C.J. Wei, and G.J. Nabel Structural and genetic basis for development of broadly neutralizing influenza antibodies Nature 489 2012 566 570
130. J. Jardine, J.P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P.S. Huang, S. MacPherson, M. Jones, T. Nieusma, J. Mathison, D. Baker, A.B. Ward, D.R. Burton, L. Stamatatos, D. Nemazee, I.A. Wilson, and W.R. Schief Rational HIV immunogen design to target specific germline B cell receptors Science 340 2013 711 716
131. A.T. McGuire, S. Hoot, A.M. Dreyer, A. Lippy, A. Stuart, K.W. Cohen, J. Jardine, S. Menis, J.F. Scheid, A.P. West, W.R. Schief, and L. Stamatatos Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies J. Exp. Med. 210 2013 655 663
132. P.D. Kwong, J.R. Mascola, and G.J. Nabel Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning Nat. Rev. Immunol. 13 2013 693 701
133. D.W. Kulp, and W.R. Schief Advances in structure-based vaccine design Curr. Opin. Virol. 3 2013 322 331
134. H. Mouquet, and M.C. Nussenzweig HIV: Roadmaps to a vaccine Nature 496 2013 441 442
135. A.P. West Jr., R. Diskin, M.C. Nussenzweig, and P.J. Bjorkman Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 Proc. Natl. Acad. Sci. U. S. A. 109 2012 E2083 E2090
136. B.F. Keele, E.E. Giorgi, J.F. Salazar-Gonzalez, J.M. Decker, K.T. Pham, M.G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, X. Wei, C. Jiang, J.L. Kirchherr, F. Gao, J.A. Anderson, L.H. Ping, R. Swanstrom, G.D. Tomaras, W.A. Blattner, P.A. Goepfert, J.M. Kilby, M.S. Saag, E.L. Delwart, M.P. Busch, M.S. Cohen, D.C. Montefiori, B.F. Haynes, B. Gaschen, G.S. Athreya, H.Y. Lee, N. Wood, C. Seoighe, A.S. Perelson, T. Bhattacharya, B.T. Korber, B.H. Hahn, and G.M. Shaw Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection Proc. Natl. Acad. Sci. U. S. A. 105 2008 7552 7557
137. E.M. Bunnik, Z. Euler, M.R. Welkers, B.D. Boeser-Nunnink, M.L. Grijsen, J.M. Prins, and H. Schuitemaker Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level Nat. Med. 16 2010 995 997
138. C.A. Derdeyn, J.M. Decker, F. Bibollet-Ruche, J.L. Mokili, M. Muldoon, S.A. Denham, M.L. Heil, F. Kasolo, R. Musonda, B.H. Hahn, G.M. Shaw, B.T. Korber, S. Allen, and E. Hunter Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission Science 303 2004 2019 2022
139. C.A. Derdeyn, and E. Hunter Viral characteristics of transmitted HIV Curr. Opin. HIV AIDS 3 2008 16 21
140. T.L. van den Kerkhof, K.A. Feenstra, Z. Euler, M.J. van Gils, L.W. Rijsdijk, B.D. Boeser-Nunnink, J. Heringa, H. Schuitemaker, and R.W. Sanders HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity Retrovirology 10 2013 102
141. T. Schiffner, Q.J. Sattentau, and L. Dorrell Development of prophylactic vaccines against HIV-1 Retrovirology 10 2013 72
142. M.P. Girard, T. Cherian, Y. Pervikov, and M.P. Kieny A review of vaccine research and development: human acute respiratory infections Vaccine 23 2005 5708 5724
143. A. Moeller, R.N. Kirchdoerfer, C.S. Potter, B. Carragher, and I.A. Wilson Organization of the influenza virus replication machinery Science 338 2012 1631 1634
144. S. Tong, X. Zhu, Y. Li, M. Shi, J. Zhang, M. Bourgeois, H. Yang, X. Chen, S. Recuenco, J. Gomez, L.M. Chen, A. Johnson, Y. Tao, C. Dreyfus, W. Yu, R. McBride, P.J. Carney, A.T. Gilbert, J. Chang, Z. Guo, C.T. Davis, J.C. Paulson, J. Stevens, C.E. Rupprecht, E.C. Holmes, I.A. Wilson, and R.O. Donis New world bats harbor diverse influenza A viruses PLoS Pathog. 9 2013 e1003657
145. S.J. Gamblin, and J.J. Skehel Influenza hemagglutinin and neuraminidase membrane glycoproteins J. Biol. Chem. 285 2010 28403 28409
146. W. Gerhard The role of the antibody response in influenza virus infection Curr. Top. Microbiol. Immunol. 260 2001 171 190
147. M. Knossow, and J.J. Skehel Variation and infectivity neutralization in influenza Immunology 119 2006 1 7
148. P.F. Wright Vaccine preparedness - are we ready for the next influenza pandemic? N. Engl. J. Med. 358 2008 2540 2543
149. A. Dereeper, V. Guignon, G. Blanc, S. Audic, S. Buffet, F. Chevenet, J.F. Dufayard, S. Guindon, V. Lefort, M. Lescot, J.M. Claverie, and O. Gascuel Phylogeny.fr: robust phylogenetic analysis for the non-specialist Nucleic Acids Res. 36 2008 W465 W469
150. S.J. Gamblin, L.F. Haire, R.J. Russell, D.J. Stevens, B. Xiao, Y. Ha, N. Vasisht, D.A. Steinhauer, R.S. Daniels, A. Elliot, D.C. Wiley, and J.J. Skehel The structure and receptor binding properties of the 1918 influenza hemagglutinin Science 303 2004 1838 1842
151. I.A. Wilson, J.J. Skehel, and D.C. Wiley Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution Nature 289 1981 366 373
152. C. Bottcher, K. Ludwig, A. Herrmann, M. van Heel, and H. Stark Structure of influenza haemagglutinin at neutral and at fusogenic pH by electron cryo-microscopy FEBS Lett. 463 1999 255 259
153. A. Harris, G. Cardone, D.C. Winkler, J.B. Heymann, M. Brecher, J.M. White, and A.C. Steven Influenza virus pleiomorphy characterized by cryoelectron tomography Proc. Natl. Acad. Sci. U. S. A. 103 2006 19123 19127
154. I. Braakman, H. Hoover-Litty, K.R. Wagner, and A. Helenius Folding of influenza hemagglutinin in the endoplasmic reticulum J. Cell Biol. 114 1991 401 411
155. J. Chen, K.H. Lee, D.A. Steinhauer, D.J. Stevens, J.J. Skehel, and D.C. Wiley Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation Cell 95 1998 409 417
156. J.J. Skehel, and D.C. Wiley Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin Annu. Rev. Biochem. 69 2000 531 569
157. N.K. Sauter, M.D. Bednarski, B.A. Wurzburg, J.E. Hanson, G.M. Whitesides, J.J. Skehel, and D.C. Wiley Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study Biochemistry 28 1989 8388 8396
158. J.J. Skehel, and D.C. Wiley Influenza haemagglutinin Vaccine 20 Suppl. 2 2002 S51 S54
159. C.E. van de Sandt, J.H. Kreijtz, and G.F. Rimmelzwaan Evasion of influenza A viruses from innate and adaptive immune responses Viruses 4 2012 1438 1476
160. A.J. Caton, G.G. Brownlee, J.W. Yewdell, and W. Gerhard The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell 31 1982 417 427
161. D.C. Wiley, I.A. Wilson, and J.J. Skehel Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation Nature 289 1981 373 378
162. S. Schultz-Cherry, and J.C. Jones Influenza vaccines: the good, the bad, and the eggs Adv. Virus Res. 77 2010 63 84
163. J.R. Chen, C. Ma, and C.H. Wong Vaccine design of hemagglutinin glycoprotein against influenza Trends Biotechnol. 29 2011 426 434
164. L.C. Lambert, and A.S. Fauci Influenza vaccines for the future N. Engl. J. Med. 363 2010 2036 2044
165. F. Carrat, and A. Flahault Influenza vaccine: the challenge of antigenic drift Vaccine 25 2007 6852 6862
166. G. Bommakanti, M.P. Citron, R.W. Hepler, C. Callahan, G.J. Heidecker, T.A. Najar, X. Lu, J.G. Joyce, J.W. Shiver, D.R. Casimiro, J. ter Meulen, X. Liang, and R. Varadarajan Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge Proc. Natl. Acad. Sci. U. S. A. 107 2010 13701 13706
167. G.K. Hirst The quantitative determination of influenza virus and antibodies by means of red cell agglutination J. Exp. Med. 75 1942 49 64
168. M. Knossow, M. Gaudier, A. Douglas, B. Barrere, T. Bizebard, C. Barbey, B. Gigant, and J.J. Skehel Mechanism of neutralization of influenza virus infectivity by antibodies Virology 302 2002 294 298
169. J. Sui, W.C. Hwang, S. Perez, G. Wei, D. Aird, L.M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N.J. Cox, L.A. Bankston, R.O. Donis, R.C. Liddington, and W.A. Marasco Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses Nat. Struct. Mol. Biol. 16 2009 265 273
170. N.J. Temperton, K. Hoschler, D. Major, C. Nicolson, R. Manvell, V.M. Hien, Q. Ha do, M. de Jong, M. Zambon, Y. Takeuchi, and R.A. Weiss A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies Influenza Other Respir. Viruses 1 2007 105 112
171. J.A. Belser, J.M. Katz, and T.M. Tumpey The ferret as a model organism to study influenza A virus infection Dis. Model. Mech. 4 2011 575 579
172. D.G. Higgins, and P.M. Sharp CLUSTAL: a package for performing multiple sequence alignment on a microcomputer Gene 73 1988 237 244
173. X. Saelens, P. Vanlandschoot, W. Martinet, M. Maras, S. Neirynck, R. Contreras, W. Fiers, and W.M. Jou Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin Eur. J. Biochem. 260 1999 166 175
174. C.J. Wei, L. Xu, W.P. Kong, W. Shi, K. Canis, J. Stevens, Z.Y. Yang, A. Dell, S.M. Haslam, I.A. Wilson, and G.J. Nabel Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus J. Virol. 82 2008 6200 6208
175. W.C. Weldon, B.Z. Wang, M.P. Martin, D.G. Koutsonanos, I. Skountzou, and R.W. Compans Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin PLoS One 5 2010
176. R.P. de Vries, C.H. Smit, E. de Bruin, A. Rigter, E. de Vries, L.A. Cornelissen, D. Eggink, N.P. Chung, J.P. Moore, R.W. Sanders, C.H. Hokke, M. Koopmans, P.J. Rottier, and C.A. de Haan Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin J. Virol. 86 2012 11735 11744
177. Z. Biesova, M.A. Miller, R. Schneerson, J. Shiloach, K.Y. Green, J.B. Robbins, and J.M. Keith Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus Vaccine 27 2009 6234 6238
178. A.H. Ellebedy, and R. Ahmed Re-engaging cross-reactive memory B cells: the influenza puzzle Front. Immunol. 3 2012 53
179. D. Corti, A.L. Suguitan Jr., D. Pinna, C. Silacci, B.M. Fernandez-Rodriguez, F. Vanzetta, C. Santos, C.J. Luke, F.J. Torres-Velez, N.J. Temperton, R.A. Weiss, F. Sallusto, K. Subbarao, and A. Lanzavecchia Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine J. Clin. Invest. 120 2010 1663 1673
180. J.C. Krause, T. Tsibane, T.M. Tumpey, C.J. Huffman, C.F. Basler, and J.E. Crowe Jr. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin J. Virol. 85 2011 10905 10908
181. J.R. Whittle, R. Zhang, S. Khurana, L.R. King, J. Manischewitz, H. Golding, P.R. Dormitzer, B.F. Haynes, E.B. Walter, M.A. Moody, T.B. Kepler, H.X. Liao, and S.C. Harrison Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin Proc. Natl. Acad. Sci. U. S. A. 108 2011 14216 14221
182. J. Wrammert, D. Koutsonanos, G.M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W.I. Lipkin, A. Mehta, B. Razavi, C. Del Rio, N.Y. Zheng, J.H. Lee, M. Huang, Z. Ali, K. Kaur, S. Andrews, R.R. Amara, Y. Wang, S.R. Das, C.D. O'Donnell, J.W. Yewdell, K. Subbarao, W.A. Marasco, M.J. Mulligan, R. Compans, R. Ahmed, and P.C. Wilson Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection J. Exp. Med. 208 2011 181 193
183. M. Hong, P.S. Lee, R.M. Hoffman, X. Zhu, J.C. Krause, N.S. Laursen, S.I. Yoon, L. Song, L. Tussey, J.E. Crowe Jr., A.B. Ward, and I.A. Wilson Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site J. Virol. 87 2013 12471 12480
184. J. Sun, U.J. Kudahl, C. Simon, Z. Cao, E.L. Reinherz, and V. Brusic Large-scale analysis of B-cell epitopes on influenza virus hemagglutinin - implications for cross-reactivity of neutralizing antibodies Front. Immunol. 5 2014 38
185. A.K. Kashyap, J. Steel, A.F. Oner, M.A. Dillon, R.E. Swale, K.M. Wall, K.J. Perry, A. Faynboym, M. Ilhan, M. Horowitz, L. Horowitz, P. Palese, R.R. Bhatt, and R.A. Lerner Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies Proc. Natl. Acad. Sci. U. S. A. 105 2008 5986 5991
186. R. Xu, J.C. Krause, R. McBride, J.C. Paulson, J.E. Crowe Jr., and I.A. Wilson A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin Nat. Struct. Mol. Biol. 20 2013 363 370
187. D. Corti, J. Voss, S.J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S.G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, C. Silacci, B.M. Fernandez-Rodriguez, G. Agatic, S. Bianchi, I. Giacchetto-Sasselli, L. Calder, F. Sallusto, P. Collins, L.F. Haire, N. Temperton, J.P. Langedijk, J.J. Skehel, and A. Lanzavecchia A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Science 333 2011 850 856
188. D.C. Ekiert, G. Bhabha, M.A. Elsliger, R.H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I.A. Wilson Antibody recognition of a highly conserved influenza virus epitope Science 324 2009 246 251
189. D.C. Ekiert, R.H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H.J. Korse, B. Brandenburg, R. Vogels, J.P. Brakenhoff, R. Kompier, M.H. Koldijk, L.A. Cornelissen, L.L. Poon, M. Peiris, W. Koudstaal, I.A. Wilson, and J. Goudsmit A highly conserved neutralizing epitope on group 2 influenza A viruses Science 333 2011 843 850
190. R.H. Friesen, P.S. Lee, E.J. Stoop, R.M. Hoffman, D.C. Ekiert, G. Bhabha, W. Yu, J. Juraszek, W. Koudstaal, M. Jongeneelen, H.J. Korse, C. Ophorst, E.C. Brinkman-van der Linden, M. Throsby, M.J. Kwakkenbos, A.Q. Bakker, T. Beaumont, H. Spits, T. Kwaks, R. Vogels, A.B. Ward, J. Goudsmit, and I.A. Wilson A common solution to group 2 influenza virus neutralization Proc. Natl. Acad. Sci. U. S. A. 111 2014 445 450
191. Y. Okuno, K. Matsumoto, Y. Isegawa, and S. Ueda Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains J. Virol. 68 1994 517 520
192. M. Throsby, E. van den Brink, M. Jongeneelen, L.L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, J. Cinatl, J. ter Meulen, I. Lasters, R. Carsetti, M. Peiris, J. de Kruif, and J. Goudsmit Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM + memory B cells PLoS One 3 2008 e3942
193. S. Khurana, C.L. Loving, J. Manischewitz, L.R. King, P.C. Gauger, J. Henningson, A.L. Vincent, and H. Golding Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease Sci. Transl. Med. 5 2013 200ra114
194. N. Jiang, J. He, J.A. Weinstein, L. Penland, S. Sasaki, X.S. He, C.L. Dekker, N.Y. Zheng, M. Huang, M. Sullivan, P.C. Wilson, H.B. Greenberg, M.M. Davis, D.S. Fisher, and S.R. Quake Lineage structure of the human antibody repertoire in response to influenza vaccination Sci. Transl. Med. 5 2013 171ra119
195. G. Georgiou, G.C. Ippolito, J. Beausang, C.E. Busse, H. Wardemann, and S.R. Quake The promise and challenge of high-throughput sequencing of the antibody repertoire Nat. Biotechnol. 32 2014 158 168
196. B.J. DeKosky, G.C. Ippolito, R.P. Deschner, J.J. Lavinder, Y. Wine, B.M. Rawlings, N. Varadarajan, C. Giesecke, T. Dorner, S.F. Andrews, P.C. Wilson, S.P. Hunicke-Smith, C.G. Willson, A.D. Ellington, and G. Georgiou High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire Nat. Biotechnol. 31 2013 166 169
197. L. Song, V. Nakaar, U. Kavita, A. Price, J. Huleatt, J. Tang, A. Jacobs, G. Liu, Y. Huang, P. Desai, G. Maksymiuk, V. Takahashi, S. Umlauf, L. Reiserova, R. Bell, H. Li, Y. Zhang, W.F. McDonald, T.J. Powell, and L. Tussey Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs PLoS One 3 2008 e2257
198. S. Khurana, S. Verma, N. Verma, C.J. Crevar, D.M. Carter, J. Manischewitz, L.R. King, T.M. Ross, and H. Golding Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus PLoS One 5 2010 e11548
199. S. Khurana, S. Verma, N. Verma, C.J. Crevar, D.M. Carter, J. Manischewitz, L.R. King, T.M. Ross, and H. Golding Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets J. Virol. 85 2011 1246 1256
200. R.M. DuBois, J.M. Aguilar-Yanez, G.I. Mendoza-Ochoa, Y. Oropeza-Almazan, S. Schultz-Cherry, M.M. Alvarez, S.W. White, and C.J. Russell The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure J. Virol. 85 2011 865 872
201. C. Xuan, Y. Shi, J. Qi, W. Zhang, H. Xiao, and G.F. Gao Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines Protein Cell 2 2011 997 1005
202. A. Jegerlehner, F. Zabel, A. Langer, K. Dietmeier, G.T. Jennings, P. Saudan, and M.F. Bachmann Bacterially produced recombinant influenza vaccines based on virus-like particles PLoS One 8 2013 e78947
203. D.C. Ekiert, A.K. Kashyap, J. Steel, A. Rubrum, G. Bhabha, R. Khayat, J.H. Lee, M.A. Dillon, R.E. O'Neil, A.M. Faynboym, M. Horowitz, L. Horowitz, A.B. Ward, P. Palese, R. Webby, R.A. Lerner, R.R. Bhatt, and I.A. Wilson Cross-neutralization of influenza A viruses mediated by a single antibody loop Nature 489 2012 526 532
204. T. Tsibane, D.C. Ekiert, J.C. Krause, O. Martinez, J.E. Crowe Jr., I.A. Wilson, and C.F. Basler Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses PLoS Pathog. 8 2012 e1003067
205. N. Pica, and P. Palese Toward a universal influenza virus vaccine: prospects and challenges Annu. Rev. Med. 64 2013 189 202
206. A.K. Harris, J.R. Meyerson, Y. Matsuoka, O. Kuybeda, A. Moran, D. Bliss, S.R. Das, J.W. Yewdell, G. Sapiro, K. Subbarao, and S. Subramaniam Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies Proc. Natl. Acad. Sci. U. S. A. 110 2013 4592 4597
207. P.A. Bullough, F.M. Hughson, J.J. Skehel, and D.C. Wiley Structure of influenza haemagglutinin at the pH of membrane fusion Nature 371 1994 37 43
208. C.M. Carr, and P.S. Kim A spring-loaded mechanism for the conformational change of influenza hemagglutinin Cell 73 1993 823 832
209. J. Chen, S.A. Wharton, W. Weissenhorn, L.J. Calder, F.M. Hughson, J.J. Skehel, and D.C. Wiley A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation Proc. Natl. Acad. Sci. U. S. A. 92 1995 12205 12209
210. G. Bommakanti, X. Lu, M.P. Citron, T.A. Najar, G.J. Heidecker, J. ter Meulen, R. Varadarajan, and X. Liang Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge J. Virol. 86 2012 13434 13444
211. Y. Lu, J.P. Welsh, and J.R. Swartz Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines Proc. Natl. Acad. Sci. U. S. A. 111 2014 125 130
212. J. Steel, A.C. Lowen, T.T. Wang, M. Yondola, Q. Gao, K. Haye, A. Garcia-Sastre, and P. Palese Influenza virus vaccine based on the conserved hemagglutinin stalk domain MBio 1 2010
213. V.V. Mallajosyula, M. Citron, X. Lu, J.T. Meulen, R. Varadarajan, and X. Liang In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin Proteins 81 2013 1759 1775
214. V.V.A. Mallajosyula, M. Citron, F. Ferrara, X. Lu, C. Callahan, G.J. Heidecker, S.P. Sarma, J.A. Flynn, N.J. Temperton, X. Liang, and R. Varadarajan Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection Proc. Natl. Acad. Sci. U. S. A. 2014 10.1073/pnas.1402766111 (in press)
215. J.H. Kim, W.G. Davis, S. Sambhara, and J. Jacob Strategies to alleviate original antigenic sin responses to influenza viruses Proc. Natl. Acad. Sci. U. S. A. 109 2012 13751 13756
216. A. Schneemann, J.A. Speir, G.S. Tan, R. Khayat, D.C. Ekiert, Y. Matsuoka, and I.A. Wilson A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin J. Virol. 86 2012 11686 11697
217. J.R. Chen, Y.H. Yu, Y.C. Tseng, W.L. Chiang, M.F. Chiang, Y.A. Ko, Y.K. Chiu, H.H. Ma, C.Y. Wu, J.T. Jan, K.I. Lin, C. Ma, and C.H. Wong Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections Proc. Natl. Acad. Sci. U. S. A. 111 2014 2476 2481
218. D. Eggink, P.H. Goff, and P. Palese Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain J. Virol. 88 2014 699 704
219. R. Hai, F. Krammer, G.S. Tan, N. Pica, D. Eggink, J. Maamary, I. Margine, R.A. Albrecht, and P. Palese Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes J. Virol. 86 2012 5774 5781
220. F. Krammer, I. Margine, R. Hai, A. Flood, A. Hirsh, V. Tsvetnitsky, D. Chen, and P. Palese H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge J. Virol. 88 2014 2340 2343
221. F. Krammer, N. Pica, R. Hai, I. Margine, and P. Palese Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies J. Virol. 87 2013 6542 6550
222. I. Margine, F. Krammer, R. Hai, N.S. Heaton, G.S. Tan, S.A. Andrews, J.A. Runstadler, P.C. Wilson, R.A. Albrecht, A. Garcia-Sastre, and P. Palese Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses J. Virol. 87 2013 10435 10446
223. P.H. Goff, D. Eggink, C.W. Seibert, R. Hai, L. Martinez-Gil, F. Krammer, and P. Palese Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies PLoS One 8 2013 e79194
224. M. Kanekiyo, C.J. Wei, H.M. Yassine, P.M. McTamney, J.C. Boyington, J.R. Whittle, S.S. Rao, W.P. Kong, L. Wang, and G.J. Nabel Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies Nature 499 2013 102 106
225. B.E. Correia, J.T. Bates, R.J. Loomis, G. Baneyx, C. Carrico, J.G. Jardine, P. Rupert, C. Correnti, O. Kalyuzhniy, V. Vittal, M.J. Connell, E. Stevens, A. Schroeter, M. Chen, S. Macpherson, A.M. Serra, Y. Adachi, M.A. Holmes, Y. Li, R.E. Klevit, B.S. Graham, R.T. Wyatt, D. Baker, R.K. Strong, J.E. Crowe Jr., P.R. Johnson, and W.R. Schief Proof of principle for epitope-focused vaccine design Nature 507 2014 201 206
226. J.S. McLellan, M. Chen, M.G. Joyce, M. Sastry, G.B. Stewart-Jones, Y. Yang, B. Zhang, L. Chen, S. Srivatsan, A. Zheng, T. Zhou, K.W. Graepel, A. Kumar, S. Moin, J.C. Boyington, G.Y. Chuang, C. Soto, U. Baxa, A.Q. Bakker, H. Spits, T. Beaumont, Z. Zheng, N. Xia, S.Y. Ko, J.P. Todd, S. Rao, B.S. Graham, and P.D. Kwong Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus Science 342 2013 592 598